loadpatents
Patent applications and USPTO patent grants for Engelman; Jeffrey.The latest application filed is for "therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor".
Patent | Date |
---|---|
Methods for treating cancer resistant to ErbB therapeutics Grant 11,008,620 - Janne , et al. May 18, 2 | 2021-05-18 |
Therapeutic Combination Of A Third-generation Egfr Tyrosine Kinase Inhibitor And A Raf Inhibitor App 20200237773 - Moody; Susan ;   et al. | 2020-07-30 |
Methods For Treating Cancer Resistant To Erbb Therapeutics App 20170073760 - Janne; Pasi A. ;   et al. | 2017-03-16 |
Methods For Treating Cancer Resistant To Erbb Therapeutics App 20140296100 - Janne; Pasi A. ;   et al. | 2014-10-02 |
Methods for treating cancer resistant to ErbB therapeutics Grant 8,715,665 - Janne , et al. May 6, 2 | 2014-05-06 |
Methods For Treating Cancer Resistant To Erbb Therapeutics App 20120225870 - Janne; Pasi A. ;   et al. | 2012-09-06 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.